Hanall Biopharma Co., Ltd. (KRX:009420)

Market Cap	2.34T +33.0%
Revenue (ttm)	155.18B +11.7%
Net Income	-5.56B
EPS	-109.48
Shares Out	50.78M
PE Ratio	n/a
Forward PE	943.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	376,397
Average Volume	476,442
Open	47,900
Previous Close	46,000
Day's Range	46,500 - 48,350
52-Week Range	24,000 - 66,600
Beta	0.91
RSI	39.91
Earnings Date	May 13, 2026

About Hanall Biopharma

Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascul...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 304
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 009420

Financial Performance

In 2025, Hanall Biopharma's revenue was 155.18 billion, an increase of 11.69% compared to the previous year's 138.94 billion. Losses were -5.56 billion, 208.0% more than in 2024.